annual meeting program - American Society of Clinical Oncology

SATURDAY
Saturday, June 5, 2010
Brd. 46C Health-related quality of life (HRQL) and progression-free survival (PFS) in
patients with recurrent ovarian cancer: Results from the CALYPSO trial.
(Abstract #5044)
M. Brundage, M. Gropp, F. Mefti, K. Mann, B. Lund, V. Gebski, G. Wolfram,
N. Reed, S. Pignata, A. Ferrero
Brd. 46D Safety and tolerability of a novel IL-12 gene therapeutic administered in
combination with carboplatin/docetaxel in patients with recurrent ovarian
cancer. (Abstract #5045)
K. Anwar, M. N. Barnes, F. J. Kelly, C. Chu, K. Cutter, J. Fewell, R. D. Alvarez
Brd. 46E Activity of docetaxel plus trabectedin in recurrent or persistent ovarian and
primary peritoneal cancer: A phase II study of the Gynecologic Oncology
Group (GOG). (Abstract #5046)
B. J. Monk, M. Sill, J. L. Walker, P. Hanjani, R. P. Edwards, J. Rotmensch,
K. De Geest, A. J. Bonebrake
Brd. 46F Phase III randomized trial of neoadjuvant chemotherapy (NAC) followed by
radical hysterectomy (RH) versus RH for bulky stage I/II cervical cancer:
Update of Japan Clinical Oncology Group (JCOG) Protocol 0102.
(Abstract #5047)
N. Katsumata, H. Yoshikawa, H. Kobayashi, T. Saito, K. Kuzuya, T. Mizunoe,
M. Hiura, T. Kasamatsu, T. Shibata, T. Kamura
Brd. 46G Prognostic role of lymph node status in primary advanced ovarian cancer
after complete resection or residual disease less than 1 cm: Results of a
meta-analysis of the AGO-OVAR meta-database. (Abstract #5048)
P. Harter, A. Reuss, J. Pfisterer, E. Pujade-Lauraine, I. L. Ray-Coquard, A. Du Bois
Brd. 46H Phase Ib study of AMG 386 combined with either pegylated liposomal
doxorubicin (PLD) or topotecan (T) in patients with advanced ovarian cancer.
(Abstract #5049)
R. M. Wenham, J. W. Leach, S. A. Scudder, B. R. Amin, C. H. Pippitt,
A. N. Gordon, N. Nanayakkara, E. Hurh, D. E. Stepan, R. J. Schilder
Brd. 47A Phase Ib study of RAD001 (R) with pegylated-liposomal doxorubicin (PLD) in
patients with advanced solid tumors. (Abstract #5050)
A. Perotti, C. Sessa, N. Colombo, G. Del Conte, A. Delmonte, T. Diena,
M. Lapresa, G. Parma, L. Viganò, L. Gianni
Brd. 47B Intraperitoneal mitoxantrone in the treatment of recurrent ascites from
progressive epithelial ovarian cancer. (Abstract #5051)
M. Marinaccio, E. Mele, E. De Marino, R. Catacchio, C. Pellegrino, F. Sozzi,
S. Schonauer
Brd. 47C The impact of adjuvant chemotherapy for stage I clear cell carcinoma of the
ovary: A retrospective Japan clear cell carcinoma study. (Abstract #5052)
M. Takano, T. Sugiyama, N. Yaegashi, S. Sagae, K. Kuzuya, Y. Udagawa,
H. Tsuda, M. Suzuki, T. Goto, Y. Kikuchi, Japan Clear Cell Carcinoma Study Group
Brd. 47D How does 18 f-FDG PET-CT scan affect clinical judgment and change
treatment decisions in patients with epithelial ovarian cancer?
(Abstract #5053)
F. Selcukbiricik, M. Ozguroglu, M. A. Ozturk, N. Ozgur, H. Turna, D. Tural,
M. Hallac, F. Demirkiran, M. Arvas, N. M. Mandel
Brd. 47E Laparoscopic hysterectomy versus abdominal hysterectomy in early-stage
endometrial cancer. (Abstract #5054)
M. J. Mourits, C. J. Bijen, K. M. Vermeulen, A. G. Zee, G. de Bock
Brd. 47F ERCC1 status in patients with locally advanced cervical cancer treated with
RT or CRT: A multicenter clinicopathologic analysis. (Abstract #5055)
C. M. Doll, A. W. Fyles, C. Aquino-Parsons, M. Pintilie, A. Klimowicz, S. Petrillo,
M. Milosevic, S. P. Lees-Miller, B. A. Clarke, A. M. Magliocco
Brd. 47G The combination of [ 18 f]fluorodeoxy-glucose and 16alpha-[ 18 f]fluoro-17betaestradiol
positron emission tomography for identifying leiomyosarcoma in
uterine smooth muscle tumors. (Abstract #5056)
Y. Yoshida, T. Kurokawa, Y. Sawamura, A. Shinagawa, F. Kotsuji
170